Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Leukemia Therapeutics Market Segmentation
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary
2. Global Leukemia Therapeutics Market Introduction
2.1. Global Leukemia Therapeutics Market - Taxonomy
2.2. Global Leukemia Therapeutics Market - Definitions
2.2.1. By Types of Leukemia
2.2.2. By Molecule
2.2.3. By Therapy
2.2.4. By Region
3. Global Leukemia Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Leukemia Therapeutics Market By Types of Leukemia, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Acute Lymphocytic Leukemia
4.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Acute Myeloid Leukemia
4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
4.3. Chronic Lymphocytic Leukemia
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.3.3. Market Opportunity Analysis
4.4. Chronic Myeloid Leukemia
4.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.4.3. Market Opportunity Analysis
4.5. Others
4.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.5.3. Market Opportunity Analysis
5. Global Leukemia Therapeutics Market By Molecule, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Biologics
5 1 1 Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Single Molecule
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Leukemia Therapeutics Market By Therapy, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Targeted Therapy
6.1.1. Tyrosine kinase inhibitor (TKI) therapy
6.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. BCL2 inhibitor therapy
6.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.1.3. Monoclonal antibody therapy
6.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3.3. Market Opportunity Analysis
6.1.4. Others
6.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.4.3. Market Opportunity Analysis
6.2. Chemotherapy
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Immunotherapy
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Leukemia Therapeutics Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. MEA
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Leukemia Therapeutics Market - Opportunity Analysis Index, By Molecule, Types of Leukemia, Therapy, , , , , and Region, 2023-2029
8. North America Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1. Acute Lymphocytic Leukemia
8.1.2. Acute Myeloid Leukemia
8.1.3. Chronic Lymphocytic Leukemia
8.1.4. Chronic Myeloid Leukemia
8.1.5. Others
8.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1. Biologics
8.2.2. Single Molecule
8.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1. Targeted Therapy
8.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
8.3.1.2. BCL2 inhibitor therapy
8.3.1.3. Monoclonal antibody therapy
8.3.1.4. Others
8.3.2. Chemotherapy
8.3.3. Immunotherapy
8.3.4. Others
8.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.4.1. USA
8.4.2. Canada
9. Europe Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Acute Lymphocytic Leukemia
9.1.2. Acute Myeloid Leukemia
9.1.3. Chronic Lymphocytic Leukemia
9.1.4. Chronic Myeloid Leukemia
9.1.5. Others
9.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Biologics
9.2.2. Single Molecule
9.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. Targeted Therapy
9.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
9.3.1.2. BCL2 inhibitor therapy
9.3.1.3. Monoclonal antibody therapy
9.3.1.4. Others
9.3.2. Chemotherapy
9.3.3. Immunotherapy
9.3.4. Others
9.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1. Germany
9.4.2. France
9.4.3. Italy
9.4.4. Spain
9.4.5. UK
9.4.6. Rest of Europe
10. Asia Pacific Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Acute Lymphocytic Leukemia
10.1.2. Acute Myeloid Leukemia
10.1.3. Chronic Lymphocytic Leukemia
10.1.4. Chronic Myeloid Leukemia
10.1.5. Others
10.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Biologics
10.2.2. Single Molecule
10.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. Targeted Therapy
10.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
10.3.1.2. BCL2 inhibitor therapy
10.3.1.3. Monoclonal antibody therapy
10.3.1.4. Others
10.3.2. Chemotherapy
10.3.3. Immunotherapy
10.3.4. Others
10.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1. China
10.4.2. Japan
10.4.3. South Korea
10.4.4. India
10.4.5. Rest of APAC
11. Latin America Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Acute Lymphocytic Leukemia
11.1.2. Acute Myeloid Leukemia
11.1.3. Chronic Lymphocytic Leukemia
11.1.4. Chronic Myeloid Leukemia
11.1.5. Others
11.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Biologics
11.2.2. Single Molecule
11.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. Targeted Therapy
11.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
11.3.1.2. BCL2 inhibitor therapy
11.3.1.3. Monoclonal antibody therapy
11.3.1.4. Others
11.3.2. Chemotherapy
11.3.3. Immunotherapy
11.3.4. Others
11.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Argentina
11.4.4. Rest of Latin America
12. MEA Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1. Acute Lymphocytic Leukemia
12.1.2. Acute Myeloid Leukemia
12.1.3. Chronic Lymphocytic Leukemia
12.1.4. Chronic Myeloid Leukemia
12.1.5. Others
12.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1. Biologics
12.2.2. Single Molecule
12.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1. Targeted Therapy
12.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
12.3.1.2. BCL2 inhibitor therapy
12.3.1.3. Monoclonal antibody therapy
12.3.1.4. Others
12.3.2. Chemotherapy
12.3.3. Immunotherapy
12.3.4. Others
12.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of MEA
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Amgen Inc.
13.2.2. AstraZeneca plc
13.2.3. Bristol-Myers Squibb Company
13.2.4. F. Hoffmann-La Roche Ltd.
13.2.5. Incyte Corp
13.2.6. Johnson & Johnson
13.2.7. Novartis International AG
13.2.8. Pfizer Inc.
13.2.9. Sanofi S.A.
13.2.10. Teva Pharmaceutical
13.2.11. Astellas Pharma
13.2.12. Otsuka Holdings Co., Ltd.
13.2.13. BeiGene
14. Research Methodology
15. Key Assumptions and Acronyms
2. Global Leukemia Therapeutics Market Introduction
2.1. Global Leukemia Therapeutics Market - Taxonomy
2.2. Global Leukemia Therapeutics Market - Definitions
2.2.1. By Types of Leukemia
2.2.2. By Molecule
2.2.3. By Therapy
2.2.4. By Region
3. Global Leukemia Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Leukemia Therapeutics Market By Types of Leukemia, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Acute Lymphocytic Leukemia
4.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Acute Myeloid Leukemia
4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
4.3. Chronic Lymphocytic Leukemia
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.3.3. Market Opportunity Analysis
4.4. Chronic Myeloid Leukemia
4.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.4.3. Market Opportunity Analysis
4.5. Others
4.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.5.3. Market Opportunity Analysis
5. Global Leukemia Therapeutics Market By Molecule, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Biologics
5 1 1 Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Single Molecule
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Leukemia Therapeutics Market By Therapy, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Targeted Therapy
6.1.1. Tyrosine kinase inhibitor (TKI) therapy
6.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. BCL2 inhibitor therapy
6.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.1.3. Monoclonal antibody therapy
6.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3.3. Market Opportunity Analysis
6.1.4. Others
6.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.4.3. Market Opportunity Analysis
6.2. Chemotherapy
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Immunotherapy
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Leukemia Therapeutics Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. MEA
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Leukemia Therapeutics Market - Opportunity Analysis Index, By Molecule, Types of Leukemia, Therapy, , , , , and Region, 2023-2029
8. North America Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1. Acute Lymphocytic Leukemia
8.1.2. Acute Myeloid Leukemia
8.1.3. Chronic Lymphocytic Leukemia
8.1.4. Chronic Myeloid Leukemia
8.1.5. Others
8.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1. Biologics
8.2.2. Single Molecule
8.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1. Targeted Therapy
8.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
8.3.1.2. BCL2 inhibitor therapy
8.3.1.3. Monoclonal antibody therapy
8.3.1.4. Others
8.3.2. Chemotherapy
8.3.3. Immunotherapy
8.3.4. Others
8.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.4.1. USA
8.4.2. Canada
9. Europe Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Acute Lymphocytic Leukemia
9.1.2. Acute Myeloid Leukemia
9.1.3. Chronic Lymphocytic Leukemia
9.1.4. Chronic Myeloid Leukemia
9.1.5. Others
9.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Biologics
9.2.2. Single Molecule
9.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. Targeted Therapy
9.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
9.3.1.2. BCL2 inhibitor therapy
9.3.1.3. Monoclonal antibody therapy
9.3.1.4. Others
9.3.2. Chemotherapy
9.3.3. Immunotherapy
9.3.4. Others
9.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1. Germany
9.4.2. France
9.4.3. Italy
9.4.4. Spain
9.4.5. UK
9.4.6. Rest of Europe
10. Asia Pacific Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Acute Lymphocytic Leukemia
10.1.2. Acute Myeloid Leukemia
10.1.3. Chronic Lymphocytic Leukemia
10.1.4. Chronic Myeloid Leukemia
10.1.5. Others
10.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Biologics
10.2.2. Single Molecule
10.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. Targeted Therapy
10.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
10.3.1.2. BCL2 inhibitor therapy
10.3.1.3. Monoclonal antibody therapy
10.3.1.4. Others
10.3.2. Chemotherapy
10.3.3. Immunotherapy
10.3.4. Others
10.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1. China
10.4.2. Japan
10.4.3. South Korea
10.4.4. India
10.4.5. Rest of APAC
11. Latin America Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Acute Lymphocytic Leukemia
11.1.2. Acute Myeloid Leukemia
11.1.3. Chronic Lymphocytic Leukemia
11.1.4. Chronic Myeloid Leukemia
11.1.5. Others
11.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Biologics
11.2.2. Single Molecule
11.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. Targeted Therapy
11.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
11.3.1.2. BCL2 inhibitor therapy
11.3.1.3. Monoclonal antibody therapy
11.3.1.4. Others
11.3.2. Chemotherapy
11.3.3. Immunotherapy
11.3.4. Others
11.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Argentina
11.4.4. Rest of Latin America
12. MEA Leukemia Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Types of Leukemia Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1. Acute Lymphocytic Leukemia
12.1.2. Acute Myeloid Leukemia
12.1.3. Chronic Lymphocytic Leukemia
12.1.4. Chronic Myeloid Leukemia
12.1.5. Others
12.2. Molecule Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1. Biologics
12.2.2. Single Molecule
12.3. Therapy Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1. Targeted Therapy
12.3.1.1. Tyrosine kinase inhibitor (TKI) therapy
12.3.1.2. BCL2 inhibitor therapy
12.3.1.3. Monoclonal antibody therapy
12.3.1.4. Others
12.3.2. Chemotherapy
12.3.3. Immunotherapy
12.3.4. Others
12.4. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of MEA
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Amgen Inc.
13.2.2. AstraZeneca plc
13.2.3. Bristol-Myers Squibb Company
13.2.4. F. Hoffmann-La Roche Ltd.
13.2.5. Incyte Corp
13.2.6. Johnson & Johnson
13.2.7. Novartis International AG
13.2.8. Pfizer Inc.
13.2.9. Sanofi S.A.
13.2.10. Teva Pharmaceutical
13.2.11. Astellas Pharma
13.2.12. Otsuka Holdings Co., Ltd.
13.2.13. BeiGene
14. Research Methodology
15. Key Assumptions and Acronyms
Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Incyte Corp
Johnson & Johnson
Novartis International AG
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceutical
Astellas Pharma
Otsuka Holdings Co., Ltd.
BeiGene
AstraZeneca plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Incyte Corp
Johnson & Johnson
Novartis International AG
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceutical
Astellas Pharma
Otsuka Holdings Co., Ltd.
BeiGene